000444233 001__ 444233
000444233 005__ 20230212181109.0
000444233 0247_ $$2CORDIS$$aG:(EU-Grant)861381$$d861381
000444233 0247_ $$2CORDIS$$aG:(EU-Call)H2020-MSCA-ITN-2019$$dH2020-MSCA-ITN-2019
000444233 0247_ $$2originalID$$acorda__h2020::861381
000444233 035__ $$aG:(EU-Grant)861381
000444233 150__ $$aNucleic Acids for Future Gene Editing, Immunotherapy and Epigenetic Sequence Modification$$y2020-04-01 - 2024-03-31
000444233 371__ $$aTHE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD$$bUOXF$$dUnited Kingdom$$ehttp://www.ox.ac.uk$$vCORDIS
000444233 371__ $$aDublin City University$$bDCU$$dIreland$$ehttp://www.dcu.ie/$$vCORDIS
000444233 371__ $$aUniversity of Reading$$bUniversity of Reading$$dUnited Kingdom$$ehttp://www.reading.ac.uk/$$vCORDIS
000444233 371__ $$aEcole Nationale Supérieure des Mines de Paris$$bChimie Paris Tech$$dFrance$$ehttp://www.chimieparistech.psl.eu$$vCORDIS
000444233 371__ $$aUNIWERSYTET WARSZAWSKI$$bUNIWARSAW$$dPoland$$ehttp://www.uw.edu.pl$$vCORDIS
000444233 371__ $$aNational Institute for Bioprocessing Research and Training$$bNIBRT$$dIreland$$ehttp://www.nibrt.ie/$$vCORDIS
000444233 371__ $$aBASECLICK GMBH$$dGermany$$ehttp://www.baseclick.eu$$vCORDIS
000444233 371__ $$aUSTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I.$$bUOCHB AVCR$$dCzech Republic$$ehttp://www.uochb.cz$$vCORDIS
000444233 371__ $$aATDBIO LIMITED$$dUnited Kingdom$$ehttp://www.atdbio.com$$vCORDIS
000444233 371__ $$aLUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN$$bLMU MUENCHEN$$dGermany$$ehttp://www.uni-muenchen.de$$vCORDIS
000444233 372__ $$aH2020-MSCA-ITN-2019$$s2020-04-01$$t2024-03-31
000444233 450__ $$aNATURE-ETN$$wd$$y2020-04-01 - 2024-03-31
000444233 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000444233 680__ $$aNucleic acid (NAs) therapies are predicted to yield major advances in the treatment of human disease and new approaches in NA design are required to extend the boundaries of today`s gene editing technologies, cancer immunotherapies, and epigenetic base manipulation tools. Current gene editing technologies involving CRISPR-Cas9, despite their wide applicability, have serious limitations involving off-target or prolonged effects that produce mutations, insertions, and deletions leading to undesired therapeutic outcomes. Questions also remain regarding the development and delivery of NAs for manipulation of T-cells, now seen as the new paradigm in cancer research. NATURE-ETN will meet this challenge by engineering new biomaterials and therapies to extend the boundaries of i.) gene editing technology, ii.) cancer immunotherapy, and iii.) epigenetic base manipulation. Our research programme involves world-leading chemists and biologists in combination with high-tech/biotech SMEs and industry partners. We will use our combined expertise in NA chemistry, DNA crystallography, materials chemistry, cell culture, and epigenetic sequencing to develop an outstanding multi-disciplinary environment were 15 Early Stage Researchers will receive unrivalled research training in the most exciting gene therapy research today. The intersectoral training provided will encompass scientific and transferable skills, an understanding of industry, and features targeted workshops in sequencing and genomics along with quality/business management and future career planning. NATURE-ETN will leverage breakthrough discoveries—some originating from our own laboratories—to provide training excellence to give our fellows a deep skillset in the translation of basic research into high functioning commercial NA biomaterials. NATURE-ETN will develop the next generation of pioneering scientific leaders in Europe where they will grow our commercial need for disruptive technologies in 21st century medicine.
000444233 909CO $$ooai:juser.fz-juelich.de:880098$$pauthority$$pauthority:GRANT
000444233 909CO $$ooai:juser.fz-juelich.de:880098
000444233 970__ $$aoai:dnet:corda__h2020::4b38f9d751ddb7b58a66a5ac3472f16c
000444233 980__ $$aG
000444233 980__ $$aCORDIS
000444233 980__ $$aAUTHORITY